A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome
Latest Information Update: 20 Jul 2023
At a glance
- Drugs Soticlestat (Primary)
- Indications Complex regional pain syndromes
- Focus Proof of concept; Therapeutic Use
- Sponsors Takeda Oncology
Most Recent Events
- 05 Jul 2023 Primary endpoint has not been met. (Change From Baseline in Mean 24-Hour Pain Intensity as Assessed by NPS Score to the End of Part A), as per Results published in the Pain Medicine
- 05 Jul 2023 Results published in the Pain Medicine
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.